Ticker brief
DRMA
last close
·
1 day
·
14 days
·
mkt cap
·
signals 14d
27
authors 14d
10
crowd 14d
+1.8σ
No price history on file for this name (likely non-equity or unlisted) — the “since then” column below stays blank.
Sentiment — last 14 days
· daily mean sentiment, 2026-10-15 → 2026-10-15 · now +0.41 (−1 bearish … +1 bullish)
Who spoke10
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @smith_will86715 | C | -3.74 | 6 | +0.54 |
| @DavidScottAdams | C | -2.62 | 6 | +0.38 |
| @BiopharmIQ | B | · | 5 | +0.46 |
| @Tickeron | C | +1.53 | 3 | +0.45 |
| @AlertsAndNews | C | -3.92 | 2 | +0.12 |
| @AccesswireNews | C | · | 1 | +0.50 |
| @OTR444 | C | +0.13 | 1 | +0.25 |
| @Greatstockpix | C | -1.40 | 1 | +0.00 |
| @MikeJTrades | C | · | 1 | +0.20 |
| @InvestorIdeas | C | -0.26 | 1 | +0.55 |
Recent signals27of 27 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-10-15 | @DavidScottAdams | +0.15 | Places five momentum names on the next day's watchlist without entry intent. | · | tweet ↗ |
| 2026-10-15 | @Tickeron | +0.35 | Maxim's lone Buy-rated $4 target implies about 500% upside. | · | tweet ↗ |
| 2026-10-15 | @AlertsAndNews | -0.20 | Recaps completed stock and options alerts, hit targets, a halt and one stopped trade. | · | tweet ↗ |
| 2026-10-15 | @DavidScottAdams | +0.60 | Expresses bullish expectations for continued momentum in five stocks into Friday. | · | tweet ↗ |
| 2026-10-15 | @DavidScottAdams | +0.35 | Promotional recap of favorable movement in five previously alerted stocks. | · | tweet ↗ |
| 2026-10-15 | @DavidScottAdams | +0.20 | Names five stocks on a power-hour watchlist without specific entry intent. | · | tweet ↗ |
| 2026-10-15 | @BiopharmIQ | +0.50 | DRMA opened up 33% after a cosmetic-study update, with further Q4 readouts highlighted. | · | tweet ↗ |
| 2026-10-15 | @BiopharmIQ | +0.25 | The author identifies consumer uptake as the next commercial test for DRMA's Tome. | · | tweet ↗ |
| 2026-10-15 | @BiopharmIQ | +0.55 | A small cosmetic study showed over 71% skin improvement after one Tome treatment as DRMA gained 33%. | · | tweet ↗ |
| 2026-10-15 | @Tickeron | +0.35 | Maxim's lone Buy-rated $4 target implies about 500% upside. | · | tweet ↗ |
| 2026-10-15 | @Tickeron | +0.65 | Positive topline cosmetic-study results drove a 46% rally. | · | tweet ↗ |
| 2026-10-15 | @BiopharmIQ | +0.50 | The tweet lists large opening biotech moves and upcoming Phase 3 catalysts. | · | tweet ↗ |
| 2026-10-15 | @BiopharmIQ | +0.50 | The post lists major opening biotech gains and the news associated with each move. | · | tweet ↗ |
| 2026-10-15 | @smith_will86715 | +0.75 | Recaps a prior DRMA call rising from $0.79 to $1.18. | · | tweet ↗ |
| 2026-10-15 | @InvestorIdeas | +0.55 | Reports positive topline cosmetic-study results, with over 71% of participants showing improvement. | · | tweet ↗ |
| 2026-10-15 | @MikeJTrades | +0.20 | Lists quantified intraday performance and direction for leading gainers. | · | tweet ↗ |
| 2026-10-15 | @DavidScottAdams | +0.70 | Celebrates a completed bullish reversal move that the author's team anticipated. | · | tweet ↗ |
| 2026-10-15 | @smith_will86715 | +0.45 | Reports DRMA was halted after an upward move. | · | tweet ↗ |
| 2026-10-15 | @smith_will86715 | +0.65 | Bullish exclamation about DRMA. | · | tweet ↗ |
| 2026-10-15 | @Greatstockpix | +0.00 | Publishes a premarket gapper watch list | · | tweet ↗ |
| 2026-10-15 | @DavidScottAdams | +0.30 | Lists six positively characterized morning movers. | · | tweet ↗ |
| 2026-10-15 | @OTR444 | +0.25 | Publishes a dated momentum watchlist with multiple company-specific catalysts. | · | tweet ↗ |
| 2026-10-15 | @smith_will86715 | +0.75 | Strong bullish exclamation about DRMA. | · | tweet ↗ |
| 2026-10-15 | @smith_will86715 | +0.65 | Bullish exclamation about DRMA. | · | tweet ↗ |
| 2026-10-15 | @smith_will86715 | +0.00 | Claims major DRMA news was released but gives no event details. | · | tweet ↗ |
| 2026-10-15 | @AlertsAndNews | +0.45 | Reports positive topline cosmetic-study results, with over 71% of participants showing improvement. | · | tweet ↗ |
| 2026-10-15 | @AccesswireNews | +0.50 | Dermata announced positive topline results from a cosmetic study. | · | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.